Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports ...
Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K.
You’ll find several bright planets, stars and obvious constellations in the February evening sky. The most obvious ...
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (RIGL – Research Report) and keeping the price target at ...
Orion’s right foot star is Rigel, the seventh brightest star. Rigel is a blue-white supergiant and is by far the brightest of the 10 brightest stars in terms of actual magnitude. It ranks ...
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...
Rigel will mail the definitive proxy statement ... within one of the specified categories listed in section 96(1)(a) or (b) of the Companies Act, 2008 (as amended, “South African Companies ...
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback